• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜透析患者的腹膜炎无进展生存率:考虑竞争风险的更新。

Peritonitis-free survival in peritoneal dialysis: an update taking competing risks into account.

机构信息

Registre de Dialyse Péritonéale de Langue Française, Pontoise, France.

出版信息

Nephrol Dial Transplant. 2010 Jul;25(7):2315-22. doi: 10.1093/ndt/gfq003. Epub 2010 Jan 25.

DOI:10.1093/ndt/gfq003
PMID:20103502
Abstract

BACKGROUND

Peritonitis-free survival is commonly reported in the peritoneal dialysis (PD) literature. The Kaplan-Meier method appears to be the only technique used to date, although it has known limitations for cohorts with multiple outcomes, as in PD. In the presence of these 'competing risks' outcomes, the Kaplan-Meier estimate is interpretable only under restrictive assumptions. In contrast, methods which take competing risks into account provide unbiased estimates of probabilities of outcomes as actually experienced by patients.

METHODS

We analysed peritonitis-free survival in a cohort of 8711 incident patients from the 'Registre de Dialyse Péritonéale de Langue Française' between 1 January 2000 and 31 December 2007 by calculating the cumulative incidence (CI) of the first episode of peritonitis using the Kaplan-Meier method and a method accounting for competing risks. We compared the CI in different patient groups by the log-rank test and a test developed for competing risk data, Gray's test.

RESULTS

After 5 years of PD, the CI of at least one peritonitis episode was 0.4, and the probability of any outcome was 0.96. The Kaplan-Meier method overestimated the CI by a large amount. Compared with the log-rank test, Gray's test led to different conclusions in three out of seven comparisons.

CONCLUSIONS

The competing risk approach shows that the CI of at least one peritonitis episode was lower than reported by the Kaplan-Meier method but that survival peritonitis-free and still on PD was overall low. The competing risk approach provides estimates which have a clearer interpretation than Kaplan-Meier methods and could be more widely used in PD research.

摘要

背景

在腹膜透析(PD)文献中,常报道腹膜炎无生存时间。迄今为止,似乎只有 Kaplan-Meier 方法被使用,但对于 PD 中存在多种结局的队列,它存在已知的局限性。在存在这些“竞争风险”结局的情况下,Kaplan-Meier 估计仅在限制性假设下才可解释。相比之下,考虑竞争风险的方法可提供患者实际经历的结局概率的无偏估计。

方法

我们通过使用 Kaplan-Meier 方法和考虑竞争风险的方法计算 2000 年 1 月 1 日至 2007 年 12 月 31 日期间来自“法国腹膜透析登记处”的 8711 例新发病例队列的腹膜炎无生存时间,并对累积发生率(CI)进行分析。我们通过对数秩检验和适用于竞争风险数据的 Gray 检验比较了不同患者组的 CI。

结果

在 PD 5 年后,至少发生一次腹膜炎的 CI 为 0.4,任何结局的概率为 0.96。Kaplan-Meier 方法大大高估了 CI。与对数秩检验相比,在七次比较中有三次,Gray 检验得出了不同的结论。

结论

竞争风险方法表明,至少发生一次腹膜炎的 CI 低于 Kaplan-Meier 方法报告的 CI,但腹膜炎无生存且仍在 PD 治疗的患者的生存情况总体较低。竞争风险方法提供的估计比 Kaplan-Meier 方法更具解释性,可更广泛地用于 PD 研究。

相似文献

1
Peritonitis-free survival in peritoneal dialysis: an update taking competing risks into account.腹膜透析患者的腹膜炎无进展生存率:考虑竞争风险的更新。
Nephrol Dial Transplant. 2010 Jul;25(7):2315-22. doi: 10.1093/ndt/gfq003. Epub 2010 Jan 25.
2
Peritoneal dialysis in elderly patients: report from the French Peritoneal Dialysis Registry (RDPLF).老年患者的腹膜透析:法国腹膜透析登记处(RDPLF)的报告。
Nephrol Dial Transplant. 2010 Jan;25(1):255-62. doi: 10.1093/ndt/gfp375. Epub 2009 Aug 7.
3
Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand.澳大利亚和新西兰初治透析患者的透析方式与感染性死亡率的关联
Am J Kidney Dis. 2009 Feb;53(2):290-7. doi: 10.1053/j.ajkd.2008.06.032. Epub 2008 Sep 21.
4
Therapy outcome in peritoneal dialysis patients transferred from haemodialysis.从血液透析转为腹膜透析患者的治疗结果
Nephrol Dial Transplant. 2009 Sep;24(9):2889-94. doi: 10.1093/ndt/gfp132. Epub 2009 Apr 2.
5
Comparison of peritoneal dialysis practice patterns and outcomes between a Canadian and a Chinese centre.加拿大和中国两家医疗中心腹膜透析治疗模式与治疗效果的比较
Nephrol Dial Transplant. 2008 Dec;23(12):4021-8. doi: 10.1093/ndt/gfn372. Epub 2008 Sep 12.
6
On the importance of accounting for competing risks in pediatric cancer trials designed to delay or avoid radiotherapy: I. Basic concepts and first analyses.论在旨在延迟或避免放疗的儿科癌症试验中考虑竞争风险的重要性:I. 基本概念与初步分析。
Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1493-9. doi: 10.1016/j.ijrobp.2009.03.035. Epub 2009 Jul 4.
7
Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications.腹膜透析患者的腹腔内压力:与腹腔容积、体型及腹膜透析相关并发症的关系
Nephrol Dial Transplant. 2007 May;22(5):1437-44. doi: 10.1093/ndt/gfl745. Epub 2007 Feb 17.
8
Is assisted peritoneal dialysis associated with technique survival when competing events are considered?在考虑竞争事件时,辅助性腹膜透析与技术存活率相关吗?
Clin J Am Soc Nephrol. 2012 Apr;7(4):612-8. doi: 10.2215/CJN.10161011. Epub 2012 Feb 16.
9
Cumulative incidence in competing risks data and competing risks regression analysis.竞争风险数据中的累积发病率及竞争风险回归分析。
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):559-65. doi: 10.1158/1078-0432.CCR-06-1210.
10
Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations.既往肾移植失败对澳大利亚和新西兰患者群体腹膜透析结局的影响。
Nephrol Dial Transplant. 2006 Mar;21(3):776-83. doi: 10.1093/ndt/gfi248. Epub 2005 Nov 9.

引用本文的文献

1
Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death.估算死亡竞争风险下包裹性腹膜硬化症的风险。
Nephrol Dial Transplant. 2019 Sep 1;34(9):1585-1591. doi: 10.1093/ndt/gfz034.
2
Differential Mortality and the Excess Rates of Hip Fracture Associated With Type 2 Diabetes: Accounting for Competing Risks in Fracture Prediction Matters.2 型糖尿病相关髋部骨折的差异死亡率和超额率:考虑到骨折预测中的竞争风险很重要。
J Bone Miner Res. 2018 Aug;33(8):1417-1421. doi: 10.1002/jbmr.3435. Epub 2018 May 3.
3
Effects of Alanyl-Glutamine Treatment on the Peritoneal Dialysis Effluent Proteome Reveal Pathomechanism-Associated Molecular Signatures.
丙氨酰-谷氨酰胺治疗对腹膜透析流出液蛋白质组的影响揭示了与发病机制相关的分子特征。
Mol Cell Proteomics. 2018 Mar;17(3):516-532. doi: 10.1074/mcp.RA117.000186. Epub 2017 Dec 4.
4
Functional and Transcriptomic Characterization of Peritoneal Immune-Modulation by Addition of Alanyl-Glutamine to Dialysis Fluid.添加丙氨酰-谷氨酰胺对透析液进行腹膜免疫调节的功能和转录组学特征。
Sci Rep. 2017 Jul 24;7(1):6229. doi: 10.1038/s41598-017-05872-2.
5
Addition of Alanyl-Glutamine to Dialysis Fluid Restores Peritoneal Cellular Stress Responses - A First-In-Man Trial.在透析液中添加丙氨酰-谷氨酰胺可恢复腹膜细胞应激反应——一项首次人体试验。
PLoS One. 2016 Oct 21;11(10):e0165045. doi: 10.1371/journal.pone.0165045. eCollection 2016.
6
Is there such a thing as biocompatible peritoneal dialysis fluid?是否存在生物相容的腹膜透析液?
Pediatr Nephrol. 2017 Oct;32(10):1835-1843. doi: 10.1007/s00467-016-3461-y. Epub 2016 Oct 8.
7
Upper gastrointestinal bleeding as a risk factor for dialysis and all-cause mortality: a cohort study of chronic kidney disease patients in Taiwan.上消化道出血作为透析和全因死亡率的危险因素:台湾慢性肾脏病患者的队列研究
BMJ Open. 2016 May 5;6(5):e010439. doi: 10.1136/bmjopen-2015-010439.
8
Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.卡普兰-迈耶生存分析高估了翻修关节成形术的风险:一项荟萃分析。
Clin Orthop Relat Res. 2015 Nov;473(11):3431-42. doi: 10.1007/s11999-015-4235-8.
9
Would increasing centre volumes improve patient outcomes in peritoneal dialysis? A registry-based cohort and Monte Carlo simulation study.增加中心容量是否会改善腹膜透析患者的预后?基于登记的队列研究和蒙特卡罗模拟研究。
BMJ Open. 2013 Jun 20;3(6):e003092. doi: 10.1136/bmjopen-2013-003092.
10
Modelling competing risks in nephrology research: an example in peritoneal dialysis.肾脏病学研究中的竞争风险建模:腹膜透析的一个实例
BMC Nephrol. 2013 May 24;14:110. doi: 10.1186/1471-2369-14-110.